FDA Approves sNDA for Oral Erectile Dysfunction Treatment

Article

The FDA has approved a supplemental new drug application for avanafil (Stendra) to treat erectile dysfunction in men.

VIVUS, Inc. and Auxilium Pharmaceuticals, Inc. today announced that the FDA has approved a supplemental new drug application for avanafil (Stendra), a phosphodiesterase type 5 inhibitor that treats erectile dysfunction (ED) in men aged 18 years and older.

According to a news release from the companies, Stendra “is available in multiple dosage strengths (50, 100 and 200 mg tablets) and may be taken with or without food and moderate alcohol consumption (up to 3 drinks).” In clinical studies, when compared to placebo, Stendra “helped more men achieve an erection in as early as approximately 15 minutes that lasted long enough to successfully complete sexual intercourse.”

Based on data from the Massachusetts Male Aging Study, researchers estimate that 52% of men over 40 years of age experience some degree of ED, defined as “the inability to attain or maintain a penile erection for sufficient sexual performance.”

To read the full story from HCPLive.com, click here.

Related Videos
Image credit:  Gorodenkoff | stock.adobe.com
Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Various healthy foods -- Image credit: New Africa | stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki | stock.adobe.com
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.